Weekly Low-Dose Regimen of Decitabine and Venetoclax as Effective as Higher Dose | ASH Clinical News | American Society of Hematology
Lara C. Pullen, PhD, is a freelance medical writer in Chicago, Illinois. A metronomic, low-dose schedule of decitabine and venetoclax was deemed to be a safe and effective treatment for patients with myeloid malignancies. Patients with acute myeloid leukemia (AML) who received the combination experienced a median overall survival (OS) of 16.1 months, and patients with TP53 -mutated disease had an OS of 11.3 months. Mendel Goldfinger, MD, of Montefiore Medical Center in Bronx, New York, and colleagues
